Browse > Article

A case report of Hand-foot syndrome due to sorafenib with Jaungo  

Kang, Yong-hwi (Institute of Traditional Medicine and Bioscience, Dunsan Hospital of Daejeon University)
Lee, Ga-young (Institute of Traditional Medicine and Bioscience, Dunsan Hospital of Daejeon University)
Park, Chan-Ran (Institute of Traditional Medicine and Bioscience, Dunsan Hospital of Daejeon University)
Cho, Jung-hyo (Institute of Traditional Medicine and Bioscience, Dunsan Hospital of Daejeon University)
Son, Chang-gue (Institute of Traditional Medicine and Bioscience, Dunsan Hospital of Daejeon University)
Lee, Nam-hun (Institute of Traditional Medicine and Bioscience, Dunsan Hospital of Daejeon University)
Publication Information
Journal of Haehwa Medicine / v.28, no.2, 2019 , pp. 54-59 More about this Journal
Abstract
Objectives : The purpose of this case study is to report the effect of Korean medicine on hand-foot syndrome(HFS) casued by sorafenib(nexavar) in hepatocellular carcinoma. Methods : The patient, 77-year-old patient complaining with pain, swelling and erythema on both hands and feet which is characterized as HFS was treated with Jaungo. We evaluated the symptoms by Numeric Rating Scale and pictures. Results : The symptoms of HFS has been alleviated during the treatment. Conclusions : We suggest Jaungo as one of the alternative therapies for HFS due to sorafenib.
Keywords
Sorafenib; Hand-foot syndrome; Jaungo;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Amy SC, Linda TV. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Support Cancer Therapy. 2004;1(4): 213-8.   DOI
2 Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biological and Pharmaceutical Bulletin. 2012;35(5): 717-24.   DOI
3 Wehler TC, Cao Y, Galle PR, Theobald M, Moehler M, Schimanski CC. Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. Oncology Letters. 2012;3(6):1191-4.   DOI
4 Lee JC, Kim GJ. Effects of Gamijaungo on the burn mice model and the study of hematologic, pathologic and molecular mechanism. Journal of Korean Medicine Ophthalmol ogy and Otolaryngol and Dermatology. 2015;28(1):53-67.   DOI
5 Heo JW, Eom TM, Oh JM, Choi KE, Kim HT, Seol IC, et al. Three Cases of Pressure Ulcer Treated with Hwangryunhaedok-tang Pharmacopuncture and Jaungo. Journal of Internal Korean Medicine. 2015:36(3):419-26.
6 Yeo EJ, Han JK, Kim YH. Effects of Atopy Cream-combined with Jawoongo Ointment on the Development of Atopic Dermatitis-like Skin Lesions in NC/Nga Mouse. The Journal of Korean Oriental Pediatrics. 2009;23(1):37-72.
7 Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. Journal of American Academy of Dermatology. 1991;24(3):457-61.   DOI
8 Kim TY, Kim YM. Effects of Gagam-Jawoonaek about Erythema by UV Exposure. Korean Journal of Oriental Physiology & Pathology. 2014;28(1):94-101.
9 Huang L, Li B, Hu Z. Therapeutic effect of Jiawei Huangqi Guizhi Wuwu Decoction on prevention and treatment of Xeloda-related hand-foot syndrome. Journal of Research on Integrative Medicine. 2014;2(1):26-8.
10 Zhao C, Chen J, Yu B, Wu X, Dai C, Zhou C et al. Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. Journal of Traditional Chinese Medicine. 2014;34(1):10-4.   DOI
11 Ying HF, Guo YB, Zheng L, Zhang WY, Cao Q, Shen XH. Clinical Observation of Wuwei Xuanbi Decoction of Early Intervention on Colon Cancer Patients with Hand Foot Syndrome Cause by Capecitabine. Journal of Liaoning College of Traditional Chinese Medicine. 2014;16(10):108-10.
12 Han GJ, Jang MW, Seong S, Kim SS. A Case Report of Chemotherapy-Induced Hand-Foot Syndrome Treated with Modified Dohongsamul-tang. Journal of Internal Korean Medicine. 2018;39(2):259-67.   DOI
13 McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clinical Liver Diseases. 2015:19(2):223-38.   DOI
14 Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. Journal of American Academy of Dermatology. 2009;60(2):299-305.   DOI
15 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine. 2008;359(4):378-90.   DOI
16 Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007;27(8):1125-44.   DOI
17 Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007:12(2):191-200.   DOI
18 Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001-11.   DOI
19 Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: Recommendations for management of side effects. Canadian Urological Association Journal. 2007;1:41-54.
20 Demirkan S, Gunduz O, Devrim T. Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol. Journal of the American Academy of Dermatology Case Reports. 2017;3(4):354-7.
21 Von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010; 116(20):4735-43.   DOI